Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
US Army
UBS
Queensland Health
Novartis
Express Scripts
Fish and Richardson
Accenture
Merck
Medtronic

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,551,620

« Back to Dashboard

Which drugs does patent 6,551,620 protect, and when does it expire?

Patent 6,551,620 protects APRISO and is included in one NDA.

This patent has ten patent family members in nine countries.
Summary for Patent: 6,551,620
Title: Pellet formulation for the treatment of the intestinal tract
Abstract:An orally adminsterable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.
Inventor(s): Otterbeck; Norbert (Uberlingen, DE)
Assignee: Dr. Falk Pharma GmbH (Freiburg, DE)
Application Number:09/906,494
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 6,551,620

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Valeant Pharms Intl APRISO mesalamine CAPSULE, EXTENDED RELEASE;ORAL 022301-001 Oct 31, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,551,620

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,911,778 Pellet formulation for the treatment of the intestinal tract ➤ Subscribe
6,277,412 Pellet-type formulation intended for treating the intestinal tract ➤ Subscribe
7,547,451 Pellet formulation for the treatment of the intestinal tract ➤ Subscribe
8,940,328 Pellet formulation for the treatment of the intestinal tract ➤ Subscribe
8,496,965 Pellet formulation for the treatment of the intenstinal tract ➤ Subscribe
8,337,886 Pellet formulation for the treatment of the intestinal tract ➤ Subscribe
8,956,647 Pellet formulation for the treatment of the intestinal tract ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,551,620

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal 977557 ➤ Subscribe
Japan 4088413 ➤ Subscribe
Japan 2001511441 ➤ Subscribe
Spain 2196556 ➤ Subscribe
European Patent Office 0977557 ➤ Subscribe
Denmark 0977557 ➤ Subscribe
Germany 59808642 ➤ Subscribe
Germany 19732903 ➤ Subscribe
Canada 2297832 ➤ Subscribe
Austria 241964 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Novartis
US Army
Accenture
Daiichi Sankyo
Argus Health
Chinese Patent Office
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot